Showing posts with label Janssen. Show all posts
Showing posts with label Janssen. Show all posts

Thursday, January 26, 2012

Janssen Unveils Challenges to Address Connected Care #cisummit

Janssen Healthcare Innovation Announces JANSSEN CONNECTED CARE CHALLENGE to Spur Innovation in Patient Care

Janssen Connected Care Challenge seeks transformational transition care ideas and offers awards totaling $250,000 to develop winning solutions

WASHINGTON D.C., January 26, 2012—Today Janssen Healthcare Innovation , a team within Janssen Research & Development, LLC., (Janssen), announced the Janssen Connected Care Challenge at the Health Care Innovations Summit in Washington, D.C. The Janssen Connected Care Challenge calls for technology solutions to improve the coordination of care for patients as they are being discharged from the hospital. Janssen Healthcare Innovation will award a total of $250,000 to support further development of the top three ideas that improve healthcare outcomes.

The challenge finalists will benefit from funding and external expert collaboration while retaining independence and ownership of their business concepts. By working with outside experts, Janssen is able to tap a wider range of expertise, capabilities and resources to bring new advances and solutions in healthcare.

Tuesday, June 23, 2009

New Analgesic: Nucynta (tapentadol)


When's the last time you saw a new pain pill? NUCYNTA™ (tapentadol) is a single molecule with a different approach to pain relief. It is the first new molecule in analgesia in over 25 years for the relief of moderate to severe acute pain in adults.

According to a a Phase 3 clinical study published in the June 2009 issue of Current Medical Research and Opinion, tapentadol immediate release (IR) tablets provided patients with equivalent efficacy in pain relief following orthopedic surgery and significant reduction in nausea and/or vomiting compared to oxycodone IR.

NUCYNTA™ combines opioid and nonopioid activity in one centrally acting oral analgesic.

Mu-Opioid Agonist (Ascending Pathways)
  • Work primarily on ascending pathways to inhibit transmission of pain impulses through binding to mu-opioid receptors
Norepinephrine Reuptake Inhibitor (Descending Pathways)
  • Norepinephrine reuptake inhibition works primarily on the descending pathways to enhance the inhibition of pain signaling
However, the exact mechanism of action of NUCYNTA™ is unknown. Isn't it interesting that we use so many medications that have an unknown mechanism of action? People may ask, "how does it work?" Answer: I don't know, but I know it works. To stay consistent with the "pain theme," let's talk about Lyrica (or pregabalin). This snippet is straight from the product insert: "LYRICA (pregabalin) binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin is unknown, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin) suggest that binding to the alpha2-delta subunit may be involved in pregabalin's antinociceptive and antiseizure effects in animal models." Lyrica is made by Pfizer.

There's simply so much we don't understand about pain. It's interesting to see research being done on drugs that have mysterious and unknown mechanisms of actions. We can postulate and theorize, but we can't prove how they work yet.

If you wish to learn more about Nucynta, visit: http://www.nucynta.com
Nucynta is marketed by Ortho-McNeil-Janssen Pharmaceuticals, Inc.